Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from May 1, 2011, to October 31, 2011, with the report dated November 8, 2011. The document serves as a "Block Listing Six Monthly Return" detailing the status of various share option schemes and the balance of unallotted securities under these plans.
Key Financial Metrics
The filing text does not provide data regarding revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to equity compensation scheme statistics.
| Share Option Scheme | Securities Issued/Allotted (Period) | Balance Unallotted (End of Period) |
|---|---|---|
| GlaxoSmithKline Share Option Plan - Ordinary Shares | 6,815,650 | 4,444,541 |
| GlaxoSmithKline Share Option Plan - ADS | 4,204,806 | 3,247,706 |
| Glaxo Wellcome UK Share Option Scheme | 0 | 5,119,750 |
| Glaxo Wellcome International Share Option Scheme | 0 | 13,267,156 |
| Glaxo Wellcome 1999 Share Option Plan | 0 | 1,040,000 |
| SmithKline Beecham 1989 Executive Plan (Approved - Ordinary) | 0 | 163,606 |
| SmithKline Beecham 1989 Executive Plan (Unapproved - ADS) | 0 | 275,420 |
| SmithKline Beecham 1989 Executive Plan (Unapproved - Ordinary) | 0 | 100,000 |
| GlaxoSmithKline Savings Related Share Option Scheme | 297,307 | 7,793,416 |
Material Changes
- Increases in Block Schemes: The "GlaxoSmithKline Share Option Plan - Ordinary Shares" increased by 10,000,000 securities. The "GlaxoSmithKline Share Option Plan - ADS" increased by 5,000,000 securities. The "GlaxoSmithKline Savings Related Share Option Scheme" increased by 5,000,000 securities.
- Issuances: Significant allotments occurred in the Ordinary Shares plan (6.8M), ADS plan (4.2M), and Savings Related plan (297k). No issuances were recorded for the legacy Glaxo Wellcome or SmithKline Beecham schemes during this period.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or details on contingencies. The document is a regulatory disclosure of share scheme mechanics only.
Investor Verification Checklist
- Verify the total number of shares available for future issuance across all active schemes (approx. 35.4 million unallotted).
- Confirm the dilution impact of the 11.3 million shares issued/allotted during the six-month period.
- Review the specific terms of the "GlaxoSmithKline Share Option Plan" and "Savings Related Share Option Scheme" to understand vesting schedules and exercise prices, as these saw the most activity.
- Note that legacy schemes (Glaxo Wellcome and SmithKline Beecham) remain static with no new issuances or increases.